SUBSCRIBE
SUBSCRIBE
News   Business

Kaken Pharmaceuticals To License Its Antifungal Compound KP-103 To Dow Pharmaceutical Sciences

May 11, 2006 | 
1 min read

Tokyo, May 11, 2006 (JCN) - Kaken Pharmaceutical announced on May 10 that it has concluded a licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken Pharmaceutical’s proprietary antifungal compound.

Alliances Asia
MORE ON THIS TOPIC
cutting off a row of people into pieces
Layoffs
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff
December 12, 2024
 · 
205 min read
 · 
BioSpace Editorial Staff
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel